重新点燃希望的“火炬”：ICS 可以降低慢阻肺死亡率吗？_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

 王长征

重庆医科大学附属第三医院（重庆 401120）;

Corresponding author：

王长征, Email: czwang@netease.com

Keywords：

DOI：

10.7507/1671-6205.202105094

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 王长征. 重新点燃希望的“火炬”：ICS 可以降低慢阻肺死亡率吗？. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(8): 533-535. doi: 10.7507/1671-6205.202105094 Copy

1.	Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007, 356(8): 775-789.
2.	Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet, 2016, 387(10030): 1817-1826.
3.	Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med, 2018, 378(18): 1671-1680.
4.	Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med, 2020, 383(1): 35-48.
5.	Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2020, 201(12): 1508-1516.
6.	Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease: a randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med, 2021, 203(5): 553-564.
7.	Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax, 2012, 67(11): 957-963.
8.	Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J, 2011, 5(1): 44-49.
9.	Tashkin D P, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med, 2008, 359(15): 1543-1554.
10.	The Global Initiative for Chronic Obstructive Lung Disease (GOLD), GOLD 2021 Reports. https://goldcopd.org.

1. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007, 356(8): 775-789.
2. Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet, 2016, 387(10030): 1817-1826.
3. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med, 2018, 378(18): 1671-1680.
4. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med, 2020, 383(1): 35-48.
5. Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2020, 201(12): 1508-1516.
6. Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease: a randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med, 2021, 203(5): 553-564.
7. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax, 2012, 67(11): 957-963.
8. Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J, 2011, 5(1): 44-49.
9. Tashkin D P, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med, 2008, 359(15): 1543-1554.
10. The Global Initiative for Chronic Obstructive Lung Disease (GOLD), GOLD 2021 Reports. https://goldcopd.org.

Next Article
Significance of continuous surveillance of anti-endothelial cell antibody in patients with chronic obstructive pulmonary disease

Chinese Journal of Respiratory and Critical Care Medicine

重新点燃希望的“火炬”：ICS 可以降低慢阻肺死亡率吗？

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content